Apoptosis Pathways
On this page
Direct answer
Shrinkage of the cell, chromatin condensation, membrane blebbing and phagocytosis without inflammation define apoptosis, the programmed, energy-requiring cell death executed by caspases — cysteine proteases that cleave after aspartate residues and exist as zymogens until dimerised or cleaved into activity. Two converging routes exist: the intrinsic (mitochondrial) pathway, in which BH3-only proteins tilt the Bcl-2 family balance toward Bax and Bak, permeabilising the outer membrane so cytochrome c escapes and, with Apaf-1 and procaspase-9, assembles the apoptosome; and the extrinsic pathway, where Fas ligand or tumour necrosis factor engages death receptors, recruiting FADD and caspase-8 in the death-inducing signalling complex. Both converge on executioner caspases 3, 6 and 7, whose substrate cleavage produces the apoptotic morphology. Failure of apoptosis underlies cancer and autoimmunity; excess underlies neurodegeneration and myocardial infarction.
What you must remember
- Morphology versus necrosis: apoptosis affects single cells with intact membranes, no inflammation and apoptotic bodies cleared by neighbouring phagocytes; necrosis is swelling, membrane rupture and inflammatory reaction — the first-table comparison in every pathology viva.
- Caspase classes: initiators (8 and 9, and 10), executioners (3, 6, 7) and inflammatory caspases (1, 4, 5 of the pyroptosome/pyrin world); caspase-3 is the common final executioner whose activation assays confirm apoptosis.
- Bcl-2 family: anti-apoptotic Bcl-2, Bcl-XL and Mcl-1 versus pro-apoptotic effectors Bax and Bak, with BH3-only sensors (Bad, Bid, Bim, Puma, Noxa) transmitting stress; phosphorylated Bad is sequestered by 14-3-3 — the growth-factor-withdrawal logic.
- Oncology anchor: BCL2 overexpression from the t(14;18) translocation in follicular lymphoma was the first apoptosis gene implicated in cancer; tumours treat apoptosis evasion as a hallmark, and p53-induced Bax and Puma are how genotoxic drugs kill.
- Extrinsic specificity: Fas (CD95) mutations cause autoimmune lymphoproliferative syndrome; the death receptor apoptotic signal is amplified through Bid truncation into the mitochondrial route in type II cells (hepatocytes) — why a question can legitimately bridge both pathways.
- Annexin V and TUNEL: phosphatidylserine exposed on the outer leaflet stains with annexin V; TUNEL labels DNA nick ends — the two laboratory signatures asked by name.
- Physiological roster: morphogenetic digit-webbing removal, thymic negative selection and self-reactive lymphocyte deletion; pathological inhibition in cancer, autoimmunity and viral infection (adenovirus E1B, poxvirus crmA).
How to work through a therapy-response question
A breast cancer's response to anthracycline chemotherapy is, biochemically, a question of apoptotic machinery. The drug damages DNA; p53 stabilises and induces Bax and Puma; mitochondrial outer-membrane permeabilisation releases cytochrome c; apoptosome-activated caspase-9 activates caspase-3 and the tumour cell is phagocytosed silently. Every resistance mechanism is a sabotage of that chain — p53 mutation (over half of tumours), Bcl-2 or Mcl-1 overexpression, loss of Bax, caspase downregulation — which is why Bcl-2 homology-3 mimetics such as venetoclax (a Bad-like BH3 molecule freeing Bax and Bak) were designed to lower the mitochondrial threshold in chronic lymphocytic leukaemia. The examinable insight: chemotherapy does not "poison" tumours to death; it persuades them to execute themselves.
Contrast the failure mode at the other end: in stroke penumbra and neurodegeneration the same caspases run in the wrong direction, and inhibiting apoptosis there is the therapeutic aim — one pathway, opposite prescriptions, decided by context rather than chemistry.
Where students slip
Students describe apoptosis as "cell suicide needing no energy"; ATP is required (and its exhaustion diverts damaged cells to necrosis, the mixed picture in ischaemic cores). Second, cytochrome c is released from mitochondria, not consumed there — it is the normal electron carrier between complexes III and IV that moonlights as an apoptotic cofactor once in the cytosol, a dual role examiners probe. Third, Bcl-2 sits on the mitochondrial outer membrane preventing permeabilisation; calling it a caspase inhibitor blurs the family logic. Finally, anti-Fas-induced hepatocyte death and TNF-mediated shock show the extrinsic pathway's systemic face — apoptosis is not always quiet when death receptors are systemically engaged.
Frequently asked questions
Which proteins form the apoptosome?
Cytochrome c released from mitochondria complexes with Apaf-1 and procaspase-9 (with dATP) to form the wheel-like apoptosome that activates caspase-9.
How does the extrinsic pathway of apoptosis begin?
Ligand binding to death receptors such as Fas or TNF receptor 1 recruits FADD and procaspase-8 into the death-inducing signalling complex, activating the initiator caspase.
What distinguishes apoptosis morphologically from necrosis?
Apoptosis shows cell shrinkage, chromatin condensation, blebbing and apoptotic bodies with intact membranes and no inflammation; necrosis shows swelling, rupture and inflammatory response.
Why is Bcl-2 called an oncogene without driving proliferation?
Overexpressed Bcl-2 (t(14;18) in follicular lymphoma) blocks mitochondrial cytochrome c release, preventing apoptosis and letting mutant cells accumulate — a survival advantage, not growth acceleration.
Which laboratory tests demonstrate apoptosis?
Annexin V binding to exposed phosphatidylserine and TUNEL staining of fragmented DNA ends, with caspase-3 cleavage assays as molecular confirmation.